Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Guillain-Barré Syndrome (Phase 2)
2013-000228-33Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Guillain-Barré syndrome (GBS) comparing Eculizumab + IVIg with Placebo + IVIg (2 arms). Primary endpoints: Primary safety endpoint and Functional outcome at 4 weeks. Started Oct 2013; status: terminated.
02
Drugs
eculizumab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on 2013-000228-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000228-33.